Search clinical trials for: lintuzumab

Total 101 results

Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

Leukemia

United States
European Organisation for Research and Treatment...

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
Seagen Inc.

Completed

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myeloproliferative Disorders | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Myelodysplastic Syndromes | Leukemia

United States
Actinium Pharmaceuticals

Terminated

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
Gilead Sciences

Terminated

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) (RAINIER)

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Israel, Australia, Italy, Canada, United Kingdom, Switzerland, Germany, Poland, Czechia, Belgium, France
Medical College of Wisconsin

Active, not recruiting

Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Joseph Jurcic

Withdrawn

Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia
Boehringer Ingelheim

Completed

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
Gilead Sciences

Terminated

Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF) (ATLAS)

Idiopathic Pulmonary Fibrosis

United States
Alison Walker
Seagen Inc.

Terminated

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Sichuan Cancer Hospital and Research Institute

Recruiting

Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Seagen Inc.

Completed

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome (MDS)

United States
Gilead Sciences

Completed

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Myelofibrosis

United States
Novartis Pharmaceuticals

Withdrawn

Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia (OBERON)

Acute Lymphoblastic Leukemia
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Lymphoma

United States, Belgium, Japan, Korea, Republic of, Germany, Hong Kong, Hungary, Netherlands, Singapore
Actinium Pharmaceuticals

Withdrawn

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML
M.D. Anderson Cancer Center

Completed

Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

Acute Myeloid Leukemia | Myeloproliferative Disorders | Chronic Myelomonocytic Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Nicola Goekbuget

Recruiting

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Precursor Cell Lymphoblastic Leukemia

Germany
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia (ALL2418)

Acute Lymphoid Leukemia

Italy
Pfizer

Completed

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, Spain, France, Switzerland, United Kingdom, Belgium, Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)

Lymphoma, B-Cell
Pfizer

Completed

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Leukemia | Precursor b-Cell Lymphoblastic Leukemia-Lymphoma | ACUTE LYMPHOBLASTIC LEUKEMIA

United States, Spain, Taiwan, Singapore, India, Hungary, Turkey, Poland
University of Oxford
Boehringer Ingelheim; Prostate Cancer UK

Active, not recruiting

Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy (WINGMEN) (WINGMEN)

Prostate Cancer

United Kingdom
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Acute Lymphocytic Leukemia
Gilead Sciences

Completed

Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis

Liver Fibrosis

United States
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant (GLOBAL)

Myelofibrosis | Chronic Myeloid Leukemia | Lymphoblastic Leukemia | Myelodysplasia | Acute Myeloblastic Leukemia | Lympho-proliferative Diseases

Italy
Actinium Pharmaceuticals

Recruiting

Venetoclax and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia

Leukemia

United States
Gilead Sciences

Completed

Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

Primary Sclerosing Cholangitis (PSC)

United States, Belgium, Canada, Germany, United Kingdom, Italy, Spain, Denmark, Netherlands, Sweden
Seagen Inc.

Completed

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Acute Myeloid Leukemia

United States
Versailles Hospital

Active, not recruiting

Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL (EWALL-INO)

Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)

France
Pfizer

Active, not recruiting

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Pfizer

Active, not recruiting

Besponsa Post Marketing Surveillance Study

Hematologic Maligmancy

Korea, Republic of
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission

Leukemia

United States
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

Minimal Residual Disease | Bone Marrow Transplant | Ph+ ALL

China
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

B-Cell Lymphoma

United States, Belgium, Korea, Republic of, Switzerland, France, Poland, Spain, Hong Kong, Australia, Germany, Italy, Netherlands, United Kingdom
Gilead Sciences
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

Hepatitis C | HIV | Liver Fibrosis | HIV/HCV Co-infection

United States
Pfizer

Completed

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Lymphoma, B-Cell

Japan
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Neutropenia

United States
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States, France, United Kingdom, Singapore, Korea, Republic of, Germany
Pfizer

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

ACUTE LYMPHOBLASTIC LEUKEMIA

Italy, Spain, Belgium, Germany, Hungary, Switzerland, Norway, Austria, France, Czechia, Finland, Netherlands, Sweden, Israel, Poland, Denmark, Greece, Slovakia
Beijing HuiLongGuan Hospital

Completed

Ginkgo Biloba Extract in the Treatment of Schizophrenia

Schizophrenia

China
Facet Biotech
National Cancer Institute (NCI)

Unknown

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Leukemia

United States, Canada, Netherlands, Belgium, Germany, United Kingdom, France
M.D. Anderson Cancer Center
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
Gilead Sciences

Completed

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer

United States, Russian Federation
Swedish Orphan Biovitrum

Recruiting

A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

Hereditary Tyrosinemia, Type I

China
Pfizer
UCB Pharma

Completed

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia

United States
Pfizer

Approved for marketing

Inotuzumab Ozogamicin - PF-05208773
Pfizer

Completed

InO - A Retrospective Study of UK Patients With Leukaemia (InO)

Precursor Cell Lymphoblastic Leukemia-Lymphoma

United Kingdom

Search clinical trials for: lintuzumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations